What precautions should we use with statins for women of childbearing age?

Journal of Family Practice

Volumn 55, Issue 1, 2006, Pages 75-77

  Patel, Chaitany ^a   Edgerton, Lisa ^a   Flake, Donna ^b  

^a NEW HANOVER REGIONAL MEDICAL CENTER   (United States)

^b New Hanover Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; MEVINOLIN; PRAVASTATIN; PREGNANEDIOL; SIMVASTATIN;

BREAST FEEDING; CLINICAL TRIAL; CONGENITAL MALFORMATION; CORONARY ARTERY DISEASE; DRUG CONTRAINDICATION; FETUS DEATH; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INTRAUTERINE GROWTH RETARDATION; KIDNEY MALFORMATION; LIMB MALFORMATION; LUTEAL PHASE; MENSTRUAL CYCLE; MORTALITY; OVULATION; PREGNANCY; REVIEW; STROKE; TRACHEA DISEASE; VERTEBRA MALFORMATION; ADULT; ANIMAL; ARTICLE; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; EVIDENCE BASED MEDICINE; FEMALE; FETOMATERNAL TRANSFUSION; FETUS; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANIMALS; EVIDENCE-BASED MEDICINE; FEMALE; FETUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATERNAL-FETAL EXCHANGE; PREGNANCY; RANDOMIZED CONTROLLED TRIALS;

EID: 30844471591     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (9)

1. Moore TH, Bartlett C, Burke MA, Davey Smith G, Ebrahim SB. Statins for preventing cardiovascular disease. Cochrane Database Syst Rev 2004; (2):CD004816.
2. Draft summary of reproductive toxicology studies on Mevacor NDA 21-213: Joint Meeting of the Nonprescription Drugs Advisory Committee and Endocrinologic and Metabolic Drugs Advisory Committee of the Federal Drug Administration, Merck & Co, (July 13, 2000). Available at: www.fda.gov/ohrms/dockets/ac/00/ backgrd/3622b1b_summary.pdf. Accessed on December 7, 2005.
3. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 2004; 131:287-298.
4. Plotkin D, Miller S, Nakajima S, et al. Lowering low density lipoprotein cholesterol with simvastatin, a hydroxyl-3-methylglutaryl-coenzyme a reductase inhibitor, does not affect luteal function in pre-menopausal women. J Clin Endocrinol Metabol 2002; 87:3155-3161.
5. Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004; 291:2243-2252.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
7. Mosca L, Appel JA, Benjamin EJ, et al. AHA guidelines: Evidence-based Guidelines for Cardiovascular Disease Prevention in Women. Circulation 2004; 109:672-693.
8. Herbert WNP, Braly PS, Barss VA, et al. ACOG: Guidelines for Women's Health Care. 2nd ed. Washington, DC: ACOG; 2002: 209-211.
9. US Preventive Services Task Force. Screening for lipid disorder in adults: recommendations and rationale. Internet J Intern Med 2002;3(2). Available at: www.ispub.com/ostia/index.php?xmlFilePath= journals/ijim/vol3n2/ lipid.xml. Accessed on December 8, 2005.